Company: DVAX
Filing Date: 2025-04-29
Form Type: DEFA14A
Source: 0000930413-25-001558
Chunk: 2

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-29
Form: DEFA14A
Chunk 2
---
/9 |
| Finance / Capital Allocation Experience | 8/9 |
| Public Company C-Suite Experience       | 6/9 |
| Public Health / Government Experience   | 2/9 |
| Other Public Company Board Experience   | 6/9 |

Since Dynavax’s pivot, our Board has overseen
a disciplined strategy that is generating superior value:

| · | Total stockholder                                                                     
 returns of 267% over the past five years: Far exceeding the performance of the NASDAQ 
 Biotechnology Index and the S&P Biotechnology Select Industry Index1.                 |

| · | Highly successful                                                                          
 commercialization of HEPLISAV-B®: Generated a record $268 million                          
 in net product revenue and approximately 44% U.S. total market share in 2024, representing 
 a 65% compound annual growth rate in net product revenue since 2020. 2025 is expected      
 to be a banner year for HEPLISAV-B® with anticipated net product revenue                   
 of $305-$325 million and longer-term market share leadership in the U.S. hepatitis B       
 adult vaccine market expected to grow to over $900 million in annual sales by 2030.        |

| · | Development of an innovative, differentiated pipeline: Advanced shingles vaccine with potential to disrupt a $4.4 billion           
 global market, with topline results for investigational Phase 1/2 shingles trial expected Q3 2025, and plague vaccine, for which    
 there is currently no approved vaccine in the U.S., with Phase 2 trial expected to initiate in Q3 2025. Plague vaccine is de-risked 
 as a result of a multi-year partnership with the U.S. Department of Defense.                                                        |

| · | Drove successful business development strategy during pandemic response: Established a global portfolio of CpG 1018             
 adjuvant commercial supply agreements supporting the development of COVID-19 vaccines, which generated over $950 million in net 
 product revenue from 2020 to 2022.                                                                                              |

| · | Disciplined capital strategy: Operate within a framework focused on protecting the value of our core business while                    
 balancing strategic investments for future growth. As part of this balanced approach, we are executing a $200 million share repurchase 
 program which initiated in November 2024 to be completed in 2025, $128.8 million of which has already been executed as of the end      
 of the first quarter of 2025.